Engineered immune cells aim to tame stubborn autoimmune diseases

This early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose disease has not responded to standard treatments. This approach aims to control the disease rather than provide a cure, as long-term effects are still unknown.